Comprehensive, comparative evaluation of 25 automated SARS-CoV-2 serology assays
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The onset of the COVID-19 pandemic resulted in hundreds of in vitro devices coming to market, facilitated by regulatory authorities allowing “Emergency Use,” without a prior comprehensive evaluation of performance. The World Health Organization released Target Product Profiles specifying acceptable performance characteristics for SARS-CoV-2 devices. We evaluated 16 automated serology test kits that detect IgG or Total antibodies to SARS-CoV-2, along with a further nine tests that detect IgM-specific antibodies. All IgG or Total antibody tests reported a concordance with recent infection at 83.9% or greater, with 11/16 tests having greater than 90% sensitivity. All 16 tests reported greater than 96.3% specificity. There was a low level of false reactivity when testing all 25 tests on panels of samples containing potentially cross-reacting or interfering substances. A range of results were reported when testing seroconversion and dilution panels. The study further demonstrates that a comprehensive evaluation of the performance of test kits assessed against defined specifications is essential for the selection of test kits, especially in a pandemic setting. IMPORTANCE: We have previously highlighted the fact that hundreds of SARS-CoV-2 serology tests were released months after the onset of the COVID-19 pandemic. Of the hundreds of studies investigating the test kits’ performance, few were comparative reports, using the same comprehensive sample set across multiple tests. Recently, we reported a comparative assessment of 35 rapid diagnostic tests (RDTs) or microtiter plate enzyme immunoassays (EIA) for use in low- and middle-income countries, using a large sample set from individuals with a history of COVID-19. Only a few tests meet WHO Target Product Profile performance requirements. This study reports on the performance of a further 25 automated SARS-CoV-2 immunoassays using the same panel of samples. The results highlight the better analytical and clinical performance of automated serology test kits compared with RDTs, and the importance of independent comparative assessments to inform the use and procurement of these tests for both diagnostic and epidemiological investigations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Signi fi cant di ff erences in performance were identi fi ed.”
From Point-of-care testing: state-of-the art and perspectives (2025) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“The National Serology Reference Laboratory, Australia (NRL) was funded by the World Health Organization (WHO) to perform evaluations on 35 SARS-COV-2 serology rapid diagnostic test (RDT) kits [36], with a subsequent evaluation of 25 automated assays [37].”
From Point-of-care testing: state-of-the art and perspectives (2025) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibody tests for identification of current and past infection with SARS‐CoV‐2
Geppert, J., Scandrett, K., Bigio, J., Sulis, G., Hettiarachchi, D., Mathangasinghe, Y., Weeratunga, P., Wickramasinghe, D., Bergman, H., Buckley, S. B., et al. (2022) · LSTM Online Archive (Liverpool School of Tropical Medicine) · Cited by 850
Antibody tests for identification of current and past infection with SARS-CoV-2
Deeks, J. J., Dinnes, J., Takwoingi, Y., Davenport, C., Spijker, R., Taylor-Phillips, S., Adriano, A., Beese, S., Dretzke, J., Ferrante di Ruffano, L., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652 · Cited by 655 · cited 2×
“Many studies reviewing the performance of these test kits were published (4–13), but few studies used a comprehensive panel of well-characterized samples to evaluate the performance in a manner that would normally be required by regulators (1, 14–16).”
BackgroundSerological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives.
Infantino, M. G., Damiani, A., Gobbi, F. L., Grossi, V., Lari, B., Macchia, D., Casprini, P., Veneziani, F., Villalta, D., Bizzaro, N., et al. (2020) · PubMed · Cited by 146
Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis
Gong, F., Wei, H.-X., Li, Q., Liu, L., & Li, B. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.682405 · Cited by 119
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Misra, A., & Theel, E. S. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00482-21 · Cited by 44
Black, M. A., Shen, G., Feng, X., García-Beltrán, W. F., Feng, Y., Vasudevaraja, V., Allison, D., Lin, L. H., Gindin, T. S., Astudillo, M. G., et al. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112909 · Cited by 43
Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays
Tan, S. S. Y., Saw, S., Chew, K. L., Chan, Y., Khoo, C., Pajarillaga, A., Wang, W., Tambyah, P. A., Ong, L., Jureen, R., et al. (2020) · Pathology · doi:10.1016/j.pathol.2020.09.007 · Cited by 39 · cited 1×
“Number of studies sought to assess the performance of these tests (6, 10, 13, 20, 21).”
Prince, H. E., Givens, T. S., Lapé-Nixon, M., Clarke, N. J., Schwab, D. A., Batterman, H. J., Jones, R. S., Meyer, W. A., Kapoor, H., Rowland, C. M., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01742-20 · Cited by 33 · cited 1×
“Number of studies sought to assess the performance of these tests (6, 10, 13, 20, 21).”
BackgroundRapid roll out of SARS-CoV-2 antibody testing—a concern
Andersson, M., Low, N., French, N., Greenhalgh, T., Jeffery, K., Brent, A., Ball, J., Pollock, A., McCoy, D., Iturriza-Gomara, M., et al. (2020) · BMJ · doi:10.1136/bmj.m2420 · Cited by 31 · cited 5×
“Many studies reviewing the performance of these test kits were published (4–13), but few studies used a comprehensive panel of well-characterized samples to evaluate the performance in a manner that would normally be required by regulators (1, 14–16).”
BackgroundInfluentialvan den Beld, M. J. C., Murk, J., Kluytmans, J. A. J. W., Koopmans, M., Reimerink, J. H. J., van Loo, I. H. M., Wegdam-Blans, M. C. A., Zaaijer, H. L., SARS-CoV-2, S. W. F., GeurtsvanKessel, C. H., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00767-21 · Cited by 19
Research works printed but not linked: 2
- Medical Device Coordination Group (MDCG). 2021. Guidance on performance evaluation of SARS-CoV-2 in vitro diagnostic medical devices. MDCG.
- World Health Organization. 2020. Advice on the use of point-of-care immunodiagnostic tests for COVID-19. WHO Headquarters (HQ), WHO, Geneva, Switzerland.
Cited by
Chung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H. F., & Wong, S. C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158155 · Cited by 141
Point-of-care testing: state-of-the art and perspectives
Plebani, M., Nichols, J. H., Luppa, P. B., Greene, D., Sciacovelli, L., Shaw, J., Khan, A. I., Carraro, P., Freckmann, G., Dimech, W., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0675 · Cited by 119
Self-citationNakhanova, G., Chervyakova, O. V., Shorayeva, K., Issabek, A. U., Moldagulova, S. U., Zhunushov, A. T., Ulankyzy, A., Zhakypbek, A. S., Omurtay, A. D., Куралбаевич, Н. А., et al. (2025) · Methods and Protocols · doi:10.3390/mps9010004 · Cited by 2
Semper, A. E., Rigsby, P., Otter, A. D., Mattiuzzo, G., Almond, N. M., Rowe, C., Brangel, P., Page, M., Brooks, T. J. G., Stewart, J., et al. (2022) · The Lancet Microbe · doi:10.1016/j.lanmic.2025.101329 · Cited by 3
Metadata
- Authors
- Dimech, W., Curley, S., & Cai, J. J.
- Affiliations
- National Serology Reference Laboratory , Fitzroy, Victoria, Australia
- Corresponding author
- Dimech, Wayne
- ORCID
- Dimech, Wayne
- Venue
- Microbiology Spectrum
- Publisher
- American Society for Microbiology
- Published
- 2024-01-11
- Volume
- 12
- Issue
- 1
- Pages
- e0322823-e0322823
- ISSN
- 2165-0497 (ISSN-L)
- PMC
- PMC10783060
- OpenAlex
- W4389136688
- Cited by
- 4
- References
- 21
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Microbiology Spectrum (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, automated immunoassay, IgG, IgM, test performance evaluation, sensitivity and specificity, cross-reactivity, emergency use authorization, rapid diagnostic tests, seroconversion
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Testing, Antibodies, Viral, Humans, Immunoglobulin G, Sensitivity and Specificity, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive, comparative evaluation of 25 automated SARS-CoV-2 serology assays. https://app.cochat.ai/papers/10.1128/spectrum.03228-23
- The paper
- Dimech, W., Curley, S., & Cai, J. J. (2024). Comprehensive, comparative evaluation of 25 automated SARS-CoV-2 serology assays. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03228-23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.